Medicine Dec 11
Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data Results were consistent across patient subgroups despite differences in disease severity, genotype or background therapy New findings for crizanli
Physics Dec 8
Physics

Incorporating guanidinium into perovskite solar cells stabilizes their efficiency at 19% for 1000 hours under full-sunlight testing conditions.

Medicine Dec 8
Medicine

EPFL researchers have used electrochemical imaging to take a step forward in mapping the distribution of biomolecules in tissue.